TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Kujala Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical regression of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hospitalization stay duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily urinary C- and N-terminal bone collagen telopeptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total score of OHIP-14 TR
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Histological analysis of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of lesions using RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects With Acute Radiation Esophagitis (Grade >/= 2)
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-Free Participants at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-Free Participants at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychotic Rating Scale (PSYRATS) delusions scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Left Ventricular End-systolic Volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anogenital Distance (Anus-Clitoris)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anogenital Distance (Anus-Posterior Fourchette)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High order aberrations (HOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent-reported sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Abnormal anal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of high risk HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in partial Mayo score > 2 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of transplantable grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced waiting time before transplantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Aortic Augmentation Index (AIx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall- and Prostate-Cancer specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Patient-reported side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported rectal bother
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anxiety before In-Vitro-Fertilization pickup
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain level during In-Vitro-Fertilization pickup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeliness of AED administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and nature of adverse events related to AZD4547 monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral AZD4547
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in clinical chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in haematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in urinalysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in pain status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score for Joint Replacement JR
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Scale (VAS) - Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered volume pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered DTI pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered functional MRI pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of severe hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with solicited local adverse events (AEs) (any, grade 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with solicited general AEs (any, grade 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with serious AEs (SAEs) (any, grade 3, related)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with potential immune-mediated diseases (PIMDs) (any, grade 3, related)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with haematological and biochemical laboratory abnormalities and changes from the baseline values
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Neoadjuvant Enoblituzumab as Assessed by PSA0 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapular mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best objective response rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients diagnosed with treatable OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: participant attendance at group sessions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: participant satisfaction with group sessions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Target Lesion Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of installation of a sensitive block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical response as determined by a decrease in Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) of ≥3 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologic response as determined by a decrease in C-Reactive Protein (CRP), fecal calprotectin >10% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Dropped From Study due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Breast milk retinol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Percent Time With pH <4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Verbal episodic memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: average maximum plasmatic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the pharmacokinetic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weaning Acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of anemia and micronutrient deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numerical pain scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total score from baseline in MADRS scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of Severe Clinical Rotavirus Disease
Endpoint domain: Adverse events/effects
Primary endpoint: RDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Pain Subscale Scores at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Cost of Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Steps Outside the Home Over a Two Week Period
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life (QoL) on a Short-Form 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: contamination rate in blood culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving PGA rating of clear, almost clear, or mild
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change From Baseline in Penn State Worry Questionnaire (PSWQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MTD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ocular radiation-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in PET-CT and metabolic activity/mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Cough Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of spontaneous bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: frequency of enema/digital maneuver every week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: amount of rescue laxative use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of definitive upper canines that erupt spontaneously up to 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Number of definitive upper canines that erupt spontaneously after 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Throat culture or PCR result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Oxford Shoulder Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Date of institutionalization of AD patients
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Hospice Knowledge Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospice Beliefs and Attitudes Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decision Self Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Microcirculatory blood flow during rest (RF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum blood flow (MF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory Fitness - Maximum oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of trametinib in combination with everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicities (DLTs) of the combination
Endpoint domain: Adverse events/effects
Primary endpoint: Change of SN-5 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acute technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful exclusion of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neuromuscular ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of cocaine metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regenerated cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal deaths due to bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Mental health literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Family partnership
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Participants Achieving a Complete Response or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Long-term health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative paraesophageal or sliding herniation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lift Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Free From Recurrent, Symptomatic Paroxysmal Atrial Fibrillation (PAF), Atrial Flutter (AFL), and Atrial Tachycardia (AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing a Device or Procedure-related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Average daily pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARID5B polymorphism/mutation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in renal plasma flow (RPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PGD scores in the first 72 hours after lung transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Contrast enhancement of the oculomotor nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Cerebral Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the weekly mean subjective pain index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the weekly mean pressure pain threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the weekly mean pressure pain tolerance (PPTol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal function at 6 months posttransplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrences of Infusion Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrences of Palmar-Plantar Erythrodysesthesia (PPE)
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in caries incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay of Preterm Delivery by 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improvement in QOL questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lack of deterioration in portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypnosis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pain Related Sleep Interference Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to Activate Six Sites
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Hamilton Depression Rating Scale (HDRS-17) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum plasma concentration during a dosing interval (Cmax) of esketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum plasma concentration (tmax) of esketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration (AUClast) of esketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of Navigator Threshold Alarms for Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of HMS5552
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy induced nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyaluronan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate variability (HRV) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in QT variability index (QTVI) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Regional Restitution Instability Index (R2I2) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Peak Electrocardiogram Restitution Slope (PERS) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caregiver Satisfaction With Hospital Discharge
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Motor Function Assessed by the Jebsen Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Motor Evoked Potential (MEP) Amplitudes Assessed by Stimulus Response Curve (SRC) of the Contralesional M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lesion Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to first occurrence of vascular death, stroke, myocardial infarction or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Staining behaviour of the polyps after acetic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathology of resected polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NSF
Endpoint domain: Adverse events/effects
Primary endpoint: abnormal functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mental Component Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiac-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in weight child
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in weight parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concordance of lymph node identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variation of cartilage-specific biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cholinesterase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-Item Pain Intensity Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in respiratory function post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes